Related references
Note: Only part of the references are listed.Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis
Alice Mariottini et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
B cell reconstitution following alemtuzumab induction under a belatacept-based maintenance regimen
He Xu et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis
Ron Milo et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study
Suyog Pol et al.
JOURNAL OF NEUROIMAGING (2019)
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
Xavier Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and safety of siponimod for multiple sclerosis Protocol for a systematic review and meta-analysis
Yumeng Song et al.
MEDICINE (2019)
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
Frederik Barkhof et al.
NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
Brain Atrophy in Natalizumab-treated Patients with Multiple Sclerosis: A 5-year Retrospective Study
Philipp Eisele et al.
JOURNAL OF NEUROIMAGING (2019)
Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis
F. Crescenzo et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
Jeroen Van Schependom et al.
TRANSLATIONAL NEURODEGENERATION (2019)
Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
Jorge Correale et al.
BIOMEDICINES (2019)
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
Nicola De Stefano et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
Nicola De Stefano et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS
Robert Zivadinov et al.
JOURNAL OF NEUROIMAGING (2018)
The effect of fingolimod on focal and diffuse grey matter damage in active MS patients
Albulena Bajrami et al.
JOURNAL OF NEUROLOGY (2018)
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
Bryan Ceronie et al.
JOURNAL OF NEUROLOGY (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
R. J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Imaging as an Outcome Measure in Multiple Sclerosis
Daniel Ontaneda et al.
NEUROTHERAPEUTICS (2017)
Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis
Shailender Singh et al.
JOURNAL OF NEUROINFLAMMATION (2017)
Ocrelizumab in multiple sclerosis: markers and mechanisms
Reinhard Hohlfeld et al.
LANCET NEUROLOGY (2017)
Brain Atrophy in Multiple Sclerosis Clinical Relevance and Technical Aspects
Jaume Sastre-Garriga et al.
NEUROIMAGING CLINICS OF NORTH AMERICA (2017)
Alemtuzumab CARE-MS II 5-year follow-up
Alasdair J. Coles et al.
NEUROLOGY (2017)
Cladribine to Treat Relapsing Forms of Multiple Sclerosis
Gavin Giovannoni
NEUROTHERAPEUTICS (2017)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
High dose biotin as treatment for progressive multiple sclerosis
Gary Birnbaum et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
Eva Havrdova et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
The Role of T1-weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis
Maria A. Rocca et al.
FRONTIERS IN NEUROLOGY (2017)
Lipoic acid in secondary progressive MS A randomized controlled pilot trial
Rebecca Spain et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Teriflunomide for multiple sclerosis in real-world setting
M. L. Elkjaer et al.
ACTA NEUROLOGICA SCANDINAVICA (2017)
Cell-based therapeutic strategies for multiple sclerosis
Neil J. Scolding et al.
BRAIN (2017)
Teriflunomide slows BVL in relapsing MS A reanalysis of the TEMSO MRI data set using SIENA
Ernst-Wilhelm Radue et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis
Nicola De Stefano et al.
CNS DRUGS (2017)
Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years
R. Zivadinov et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study
Mathias Buttmann et al.
NEUROLOGY (2016)
Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
Douglas L. Arnold et al.
NEUROLOGY (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
Mika Komori et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
John O'Gorman et al.
CLINICAL THERAPEUTICS (2015)
A basic overview of multiple sclerosis immunopathology
N. Grigoriadis et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis
Timothy Vollmer et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2015)
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
David H. Miller et al.
NEUROLOGY (2015)
Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes
Evanthia Bernitsas et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Intrathecal IgG Synthesis: A Resistant and Valuable Target for Future Multiple Sclerosis Treatments
Mickael Bonnan
MULTIPLE SCLEROSIS INTERNATIONAL (2015)
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
Nicola De Stefano et al.
CNS DRUGS (2014)
Multidisciplinary Management of Multiple Sclerosis Symptoms
Philippe Gallien et al.
EUROPEAN NEUROLOGY (2014)
Teriflunomide (Aubagio®) for the treatment of multiple sclerosis
Amit Bar-Or
EXPERIMENTAL NEUROLOGY (2014)
A unified cell biological perspective on axon-myelin injury
Mikael Simons et al.
JOURNAL OF CELL BIOLOGY (2014)
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
Douglas L. Arnold et al.
JOURNAL OF NEUROLOGY (2014)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
T. L. Vollmer et al.
JOURNAL OF NEUROLOGY (2014)
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsingremitting multiple sclerosis: a prospective, non-randomized pilot study
E. Portaccio et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
Angela Vidal-Jordana et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
Jerry S. Wolinsky et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity
David Bates et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Jeffrey A. Cohen et al.
LANCET (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Alasdair J. Coles et al.
LANCET (2012)
Fingolimod for Multiple Sclerosis
Daniel Pelletier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway
Robert H. Scannevin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Oxidative damage in multiple sclerosis lesions
Lukas Haider et al.
BRAIN (2011)
Treatment with Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
Jaime Ramos-Cejudo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos et al.
LANCET (2011)
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Paul O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
MR Imaging of Multiple Sclerosis
Massimo Filippi et al.
RADIOLOGY (2011)
Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis
Ruchika Shaurya Prakash et al.
BRAIN RESEARCH (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pathogenic CD8+ T Cells in Multiple Sclerosis
Manuel A. Friese et al.
ANNALS OF NEUROLOGY (2009)
Multiple Sclerosis Distribution of Inflammatory Cells in Newly Forming Lesions
Andrew P. D. Henderson et al.
ANNALS OF NEUROLOGY (2009)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
G. Comi et al.
LANCET (2009)
Multiple sclerosis: An immune or neurodegenerative disorder?
Bruce D. Trapp et al.
ANNUAL REVIEW OF NEUROSCIENCE (2008)
Campath-1H treatment of multiple sclerosis
Joanne L. Jones et al.
NEURODEGENERATIVE DISEASES (2008)
Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up
C. Buttinelli et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis
M. A. Rocca et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2007)
Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
M. Rovaris et al.
MULTIPLE SCLEROSIS (2007)
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS
D. H. Miller et al.
NEUROLOGY (2007)
The immunopathology of multiple sclerosis:: An overview
Hans Lassmann et al.
BRAIN PATHOLOGY (2007)
Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis
J. T. Chen et al.
NEUROLOGY (2006)
Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment?
DS Goodin
ANNALS OF NEUROLOGY (2006)
Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T
R Srinivasan et al.
BRAIN (2005)
Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion
MH Barnett et al.
ANNALS OF NEUROLOGY (2004)
Mechanisms of mitoxantrone in multiple sclerosis - what is known?
O Neuhaus et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2004)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The 'Immunological-Synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta
S Shapiro et al.
JOURNAL OF NEUROIMMUNOLOGY (2003)
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance
David H. Miller et al.
BRAIN (2002)
Whole brain volume changes in patients with progressive MS treated with cladribine
M Filippi et al.
NEUROLOGY (2000)
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis
PD Molyneux et al.
BRAIN (2000)
Share Paper
